AHFS Class:

• beta-Adrenergic Blocking Agents 24:20

Generic Name(s):

• Carvedilol

Carvedilol is a nonselective β-adrenergic blocking agent (β-blocker) with selective α₁-adrenergic blocking activity.1,5,16,17,18,19,59

Carvedilol is used for the management of hypertension1,2,17,59,1200 and heart failure.1,59 Carvedilol also is used to reduce the risk of cardiovascular mortality in clinically stable patients with left ventricular dysfunction (manifested as a left ventricular ejection fraction [LVEF] of 40% or less) with or without symptomatic heart failure following an acute myocardial infarction (MI).1,59,61,524,800

The choice of a β-adrenergic blocking agent (β-blocker) depends on numerous factors, including intended use, pharmacologic properties (e.g., relative β-selectivity, intrinsic sympathomimetic activity, membrane-stabilizing activity, lipophilicity), pharmacokinetics, and adverse effect profile, as well as the patient's coexisting disease states or conditions, response, and tolerance.38,47,48,49,50,51,52,53,54,55,56,57,58 While specific pharmacologic properties and other factors may appropriately influence the choice of a β-blocker in individual patients,1235 evidence of clinically important differences among the agents in terms of overall efficacy and/or safety is limited. 47,49,50,51,52,53,54,55,56,57,58 Patients who do not respond to or cannot tolerate a given β-blocker may be successfully treated with a different one.49,50,51,52,55,57,58

Hypertension

Carvedilol is used alone or in combination with other classes of antihypertensive agents in the management of hypertension.1,2,17,59,1200

Current evidence-based practice guidelines for the management of hypertension in adults generally recommend the use of drugs from 4 classes of antihypertensive agents (angiotensin-converting enzyme [ACE] inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, and thiazide diuretics).501,502,503,504,1200 Most guidelines no longer recommend β-blockers as first-line therapy for hypertension because of the lack of established superiority over other recommended drug classes and evidence from at least one study demonstrating that β-blockers may be less effective than angiotensin II receptor antagonists in preventing cardiovascular death, MI, or stroke.63,501,503,504,515,1200 However, therapy with a β-blocker may still be considered in hypertensive patients who have a compelling indication (e.g., prior MI, ischemic heart disease, heart failure) for their use or as add-on therapy in those who do not respond adequately to the preferred drug classes.501,502,503,504,523,524,527,800,1200 (See Considerations for Drug Therapy in Patients with Underlying Cardiovascular and Other Risk Factors under Uses: Hypertension, in Atenolol 24:24 and in Metoprolol 24:24.) Ultimately, choice of antihypertensive therapy should be individualized, considering the clinical characteristics of the patient (e.g., age, ethnicity/race, comorbid conditions, cardiovascular risk factors) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, costs).501,502,503,504,515,1200,1201

A 2017 multidisciplinary hypertension guideline of the American College of Cardiology (ACC), American Heart Association (AHA), and a number of other professional organizations generally recommends a target blood pressure goal (i.e., blood pressure to achieve with drug therapy and/or nonpharmacologic intervention) of less than 130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk.1200 In addition, a systolic blood pressure goal of less than 130 mm Hg generally is recommended for noninstitutionalized ambulatory patients 65 years of age or older with an average systolic blood pressure of at least 130 mm Hg.1200 These blood pressure goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of systolic blood pressure.1200,1202,1210 Previous hypertension guidelines, such as those from an expert panel of the Eighth Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), generally have recommended initiation of antihypertensive treatment in patients with a systolic blood pressure of at least 140 mm Hg or diastolic blood pressure of at least 90 mm Hg, targeted a blood pressure goal of less than 140/90 mm Hg regardless of cardiovascular risk, and used higher systolic blood pressure thresholds and targets in geriatric patients501,504,536 compared with those recommended by the 2017 ACC/AHA hypertension guideline.1200 The blood pressure thresholds used to define hypertension, the optimum blood pressure threshold at which to initiate antihypertensive drug therapy, and the ideal target blood pressure values remain controversial.501,503,504,505,506,507,508,515,523,526,530,1200,1201,1207,1209,1222,1223,1229

Most patients with hypertension, especially black patients, will require at least 2 antihypertensive drugs to achieve adequate blood pressure control.1200 In general, black hypertensive patients tend to respond better to monotherapy with thiazide diuretics or calcium-channel blocking agents than to monotherapy with β-blockers.38,45,46,501,504,1200 Although β-blockers have lowered blood pressure in all races studied, monotherapy with these agents has produced a smaller reduction in blood pressure in black hypertensive patients; however, this population difference in response does not appear to occur during combined therapy with a β-blocker and a thiazide diuretic.500 (See Race under Hypertension: Other Special Considerations for Antihypertensive Therapy, in Uses in Atenolol 24:24 and in Metoprolol 24:24.)

For additional information on the role of β-blockers in the management of hypertension, see Uses: Hypertension, in Atenolol 24:24 and in Metoprolol 24:24. For information on overall principles and expert recommendations for treatment of hypertension, see Uses: Hypertension in Adults, in the Thiazides General Statement 40:28.20. For information on overall principles and expert recommendations for treatment of hypertension in pediatric patients, see Uses: Hypertension in Pediatric Patients, in the Thiazides General Statement 40:28.20.

Heart Failure

Carvedilol is used (usually in conjunction with other heart failure therapies) in the management of mild to severe (New York Heart Association [NYHA] class II-IV) heart failure of ischemic or cardiomyopathic origin to increase survival and to reduce the risk of hospitalization.1,5,7,11,12,25,26,27,28,31,59,60,524,800 Current guidelines for the management of heart failure in adults generally recommend a combination of drug therapies to reduce morbidity and mortality, including neurohormonal antagonists (e.g., ACE inhibitors, angiotensin II receptor antagonists, angiotensin receptor-neprilysin inhibitors [ARNIs], β-blockers, aldosterone receptor antagonists), that inhibit the detrimental compensatory mechanisms in heart failure.524,701,703,800 Additional agents (e.g., cardiac glycosides, diuretics, sinoatrial modulators [i.e., ivabradine]) added to a heart failure treatment regimen in selected patients have been associated with symptomatic improvement of heart failure and/or reduction in heart failure-related hospitalizations.524,800 Experts recommend that all asymptomatic patients with reduced LVEF (American College of Cardiology Foundation [ACCF]/American Heart Association [AHA] stage B heart failure) receive therapy with an ACE inhibitor and a β-blocker to prevent symptomatic heart failure and reduce morbidity and mortality.524,800 In patients with prior or current symptoms of chronic heart failure and reduced LVEF (ACCF/AHA stage C heart failure), ACCF, AHA, and the Heart Failure Society of America (HFSA) recommend inhibition of the renin-angiotensin-aldosterone (RAA) system with an ACE inhibitor, angiotensin II receptor antagonist, or ARNI in conjunction with a β-blocker, and an aldosterone antagonist in selected patients, to reduce morbidity and mortality.800 While ACE inhibitors have been the preferred drugs for inhibition of the RAA system because of their established benefits in patients with heart failure and reduced ejection fraction, some evidence indicates that therapy with an ARNI (sacubitril/valsartan) may be more effective than ACE inhibitor therapy (enalapril) in reducing cardiovascular death and heart failure-related hospitalization in such patients.702,800 ACCF, AHA, and HFSA recommend that patients with chronic symptomatic heart failure and reduced LVEF (NYHA class II or III) who are able to tolerate an ACE inhibitor or angiotensin II receptor antagonist be switched to therapy containing an ARNI to further reduce morbidity and mortality.800

Because of favorable effects on survival and disease progression, therapy with a clinical trial-proven β-blocker (bisoprolol, carvedilol, extended-release metoprolol succinate) should be initiated as soon as the patient is diagnosed with heart failure and reduced LVEF.524 While bisoprolol, carvedilol, and extended-release metoprolol have been effective in reducing the risk of death in patients with chronic heart failure, these positive findings should not be considered indicative of a β-blocker class effect.524 Even when symptoms are mild or improve with other therapies, β-blocker therapy should not be delayed until symptoms return or the disease progresses.524 Despite concerns about β-blockade potentially masking some signs of hypoglycemia,23 patients with diabetes mellitus may be particularly likely to experience a reduction in morbidity and mortality with the use of β-blockers.23,27 If a patient cannot tolerate a β-blocker or if increasing the β-blocker dosage to optimal levels is ineffective, ivabradine should be considered an alternative or additional treatment option.701,709,710,800 Some evidence suggests that ivabradine is effective in reducing hospitalizations related to heart failure, but unlike β-blockers, ivabradine has not been shown to reduce cardiovascular mortality.707,708,710,711,712 (See Uses: Heart Failure, in Ivabradine 24:04.92.)

In individualizing the decision to use a β-blocker, clinicians should consider that clinical studies establishing the effects of these drugs on morbidity and mortality excluded patients who were hospitalized or had unstable symptoms and enrolled few patients with current or recent NYHA class IV symptoms.23,26,32,60 The efficacy of β-blockers in such patients is not known,23,33 and they may be at particular risk of deterioration following initiation of therapy with β-blockers.23,32,60 In the Carvedilol Prospective Randomized Cumulative Survival Trial (COPERNICUS) evaluating such patients with severe but stable heart failure (patients with marked fluid retention or severe pulmonary disease or requiring intensive care, IV vasodilators, or positive inotropic agents were excluded), carvedilol decreased the rate of death and the combined risk of death and hospitalization for any reason compared with placebo.31

The beneficial effects of β-blockers in the management of heart failure are thought to result principally from inhibition of the effects of the sympathetic nervous system.23 (See Description.) Although the specific effects on the heart and circulation that are responsible for progression of heart failure remain to be established, sympathetic activity can increase ventricular volumes and pressure secondary to peripheral vasoconstriction and by impairing sodium excretion by the kidneys.23,27 Other sympathetic effects (e.g., induction of cardiac hypertrophy, arrhythmogenic activity) also may be involved.23 The beneficial effect of carvedilol in patients with severe heart failure may be the result of other effects (α-adrenergic blockade, antioxidant activity, antiendothelin effects) in addition to β-adrenergic blockade.31 Collective experience indicates that long-term therapy with β-blockers, like that with ACE inhibitors, can reduce heart failure symptoms and improve clinical status in patients with chronic heart failure and also can decrease the risk of death as well as the combined risk of death and hospitalization.28,33,34,524 These beneficial effects were demonstrated in patients already receiving an ACE inhibitor, suggesting that combined inhibition of the renin-angiotensin system and sympathetic nervous system can produce additive effects.23,26,524

β-Blockers should not be used in patients with acutely decompensated heart failure requiring IV inotropic therapy and those with substantial fluid retention requiring intensive diuresis.23,31,32,60,524 In the absence of hemodynamic instability or contraindications, it has been recommended that patients with heart failure and a reduced ejection fraction who are hospitalized for a symptomatic exacerbation continue to receive maintenance treatment with standard oral therapy for heart failure (e.g., β-blocker, ACE inhibitor).524 Withholding of or reduction in β-blocker therapy should be considered only in patients hospitalized after recent initiation or increase in β-blocker therapy or in those with marked volume overload or low/marginal cardiac output.524 Initiation of β-blocker therapy in hospitalized patients is recommended once the patient's condition is stabilized (i.e., after optimization of volume status and successful discontinuance of IV diuretics, vasodilators, and inotropic agents).524 Caution should be used when initiating β-blockers in patients who have required inotrope therapy during hospitalization.524

Carvedilol has been shown in controlled studies to improve left ventricular function, symptoms, and submaximal exercise tolerance (although not in all studies) in patients with wide-ranging severity of manifestations.1,2,5,6,7,8,9,10,11,12,13,14,15,18,19 Change in NYHA classification was a secondary endpoint in all of the studies, and a trend toward improvement in NYHA class was reported in all studies.1 Subjective quality-of-life determined by a standard questionnaire was not improved in patients receiving carvedilol compared with those receiving placebo; however, global assessments by patients and clinicians supported an improvement in such assessments in patients receiving carvedilol.1

Left Ventricular Dysfunction After Acute Myocardial Infarction

Carvedilol is used to reduce the risk of cardiovascular mortality following the acute phase of MI in clinically stable patients with left ventricular dysfunction (manifested as an ejection fraction of 40% or less) with or without symptomatic heart failure.1,59,61 In these patients, when compared with those receiving placebo, carvedilol therapy initiated within 21 days after an acute MI reduced mortality from any cause by about 23%; all-cause mortality or cardiovascular hospitalization was reduced by 8%, which was not statistically significant.1,59,61 In addition, a 40% reduction in fatal and nonfatal MI was observed in patients receiving carvedilol.1,59,61 This evidence of efficacy was obtained from a large, double-blind, placebo-controlled, multicenter long-term (about 16 months) study (Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study; CAPRICORN).1,59,61 For information on the use of β-blockers during the acute phase of MI, see Uses in Metoprolol 24:24.

The benefits of long-term β-blocker therapy for secondary prevention of MI have been well established in numerous clinical studies.527,804,806,1101 Patients with MI complicated by heart failure, left ventricular dysfunction, or ventricular arrhythmias appear to derive the most benefit from long-term β-blocker therapy.527 AHA/ACCF secondary prevention guideline recommends β-blocker therapy in all patients with left ventricular systolic dysfunction (ejection fraction of 40% or less) and a prior MI; use of a β-blocker with proven mortality benefit (bisoprolol, carvedilol, or metoprolol succinate) is recommended.525,1101 (See Uses: Heart Failure.)

For additional information on the use of β-blockers in the management of MI, see Uses in Metoprolol 24:24.

Administration

Carvedilol and carvedilol phosphate are administered orally.1,59 Food has little, if any, effect on the oral bioavailability of carvedilol immediate-release tablets but may decrease the rate of absorption, resulting in reduced and delayed peak plasma concentrations.1,22 Therefore, to potentially decrease the risk of orthostatic hypotension, it is recommended that carvedilol be administered with food.1,22 In addition, the manufacturer suggests that manifestations of vasodilation in patients receiving concomitant therapy with an angiotensin-converting enzyme (ACE) inhibitor may be reduced by administering carvedilol 2 hours prior to the latter drug.16

Food increases the bioavailability of carvedilol phosphate extended-release capsules and the manufacturer states that the extended-release capsules should be taken with food.59 Carvedilol extended-release capsules should be taken once daily in the morning and should be swallowed whole; the capsule and/or its contents should not be crushed, chewed, or taken in divided doses.59 However, carvedilol extended-release capsules may be opened carefully and the entire contents sprinkled over a spoonful of applesauce, immediately prior to administration.59 The applesauce should not be warm, and the drug and applesauce mixture should be consumed in entirety.59 The drug and applesauce mixture should not be stored for future use.59 The absorption of the beads sprinkled on foods other than applesauce has not been studied.59

Dosage

Patients whose conditions are controlled with immediate-release carvedilol tablets alone or in combination with other drugs may be switched to carvedilol phosphate extended-release capsules.59 Patients who are receiving a daily carvedilol dosage of 6.25 (3.125 mg twice daily), 12.5 (6.25 mg twice daily), 25 (12.5 mg twice daily), or 50 mg (25 mg twice daily) as immediate-release tablets may be switched to a dosage of 10, 20, 40, or 80 mg once daily, respectively, as carvedilol phosphate extended-release capsules.59 Subsequent titration to higher or lower dosages may be necessary and should be guided by the patient's clinical response.59

Hypertension

Dosage of carvedilol must be individualized and adjusted according to the patient's blood pressure response and tolerance.1,59

In hypertensive patients with left ventricular dysfunction, including those with heart failure who already are receiving a cardiac glycoside, diuretic, and/or an ACE inhibitor, the manufacturer states that the usual carvedilol dosages and instructions recommended for the treatment of heart failure should be followed instead of those for hypertension, since such patients generally depend, at least in part, on β-adrenergic stimulation for maintaining cardiovascular compensation.1 (See Heart Failure under Dosage and Administration: Dosage.)

Usual Dosage

For the management of hypertension in adults, the usual initial dosage of carvedilol (as immediate-release tablets) is 6.25 mg twice daily.1,20 The manufacturer recommends that patient response and tolerance to the initial dosage and subsequent dosage adjustments be evaluated by measurement of standing systolic blood pressure 1 hour after administration of carvedilol (trough blood pressure).1 In patients whose blood pressure is not controlled adequately with the initial carvedilol dosage, dosage can be increased gradually (usually increasing dosage every 7-14 days), as tolerated up to a maximum of 50 mg daily.1,20 For patients who received an initial dosage of 6.25 mg twice daily, the dosage may be increased to 12.5 mg twice daily and, if needed, to 25 mg twice daily.1 Some experts state the usual dosage range is 12.5-50 mg daily, administered in 2 divided doses.1200

For the management of hypertension in adults, the usual initial dosage of carvedilol phosphate extended-release capsules is 20 mg once daily.59 The manufacturer recommends that patient tolerance to the initial dosage and subsequent dosage adjustments be evaluated by measurement of standing systolic blood pressure 1 hour after administration of carvedilol phosphate extended-release capsules.59 In patients whose blood pressure is not controlled adequately with the initial carvedilol phosphate dosage (given as extended-release capsules), dosage can be increased gradually (usually increasing dosage every 7-14 days) up to a maximum of 80 mg once daily (given as carvedilol phosphate extended-release capsules).59 Some experts state the usual dosage range is 20-80 mg once daily administered as extended-release capsules.1200

Addition of a diuretic to carvedilol therapy or of carvedilol to diuretic therapy can be expected to produce additive effects.1,59 When carvedilol and a thiazide diuretic are used concomitantly, an additive hypotensive response, including an increased risk of orthostatic hypotension, can be expected.1,59

Blood Pressure Monitoring and Treatment Goals

Blood pressure should be monitored regularly (i.e., monthly) during therapy and dosage of the antihypertensive drug adjusted until blood pressure is controlled.1200 If an adequate blood pressure response is not achieved, the dosage may be increased or another antihypertensive agent with demonstrated benefit and preferably with a complementary mechanism of action (e.g., ACE inhibitor, angiotensin II receptor antagonist, calcium-channel blocker, thiazide diuretic) may be added; if target blood pressure is still not achieved with the use of 2 antihypertensive agents, a third drug may be added.1200,1216 (See Uses: Hypertension.) In patients who develop unacceptable adverse effects with carvedilol, the drug should be discontinued and another antihypertensive agent from a different pharmacologic class should be initiated.1200,1216

The goal of hypertension management and prevention is to achieve and maintain optimal control of blood pressure.1200 However, the optimum blood pressure threshold for initiating antihypertensive drug therapy and specific treatment goals remain controversial.505,506,507,508,515,523,530,1201,1207,1209,1222 While previous hypertension guidelines have based target blood pressure goals on age and comorbidities,501,504,536 the 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guideline incorporates underlying cardiovascular risk into decision making regarding treatment and generally recommends the same target blood pressure (i.e., less than 130/80 mm Hg) for all adults.1200 Many patients will require at least 2 drugs from different pharmacologic classes to achieve this blood pressure goal; the potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs also should be considered when deciding a patient's blood pressure treatment goal.1200,1220

For additional information on target levels of blood pressure and on monitoring therapy in the management of hypertension, see Blood Pressure Monitoring and Treatment Goals under Dosage: Hypertension, in Dosage and Administration in the Thiazides General Statement 40:28.20.

Heart Failure

Prior to initiation of carvedilol therapy for heart failure, fluid retention should be minimized, and patients who are receiving treatment that includes a cardiac glycoside, diuretic, and/or ACE inhibitor should be stabilized with respect to the dosage of these drugs.1,22,59 Initiation of carvedilol therapy for heart failure and subsequent dosage adjustments should occur under very close medical supervision, since the risk of cardiac decompensation and/or severe hypotension is highest during the initial 30 days of therapy.1,59

For the management of mild to severe (NYHA class II-IV) heart failure, carvedilol often is administered in conjunction with other agents such as a cardiac glycoside, ACE inhibitor, and/or diuretic.1,59 Treatment with carvedilol should be initiated at a very low dosage.1,59,524 The usual initial carvedilol dosage as immediate-release tablets for the management of heart failure in adults is 3.125 mg twice daily for 2 weeks.1,524 The usual initial dosage of carvedilol phosphate extended-release capsules for the management of heart failure in adults is 10 mg once daily for 2 weeks.59 Prior to dosage increases, the patient's response and tolerance to carvedilol therapy should be determined in a clinical setting and should include an assessment of manifestations of declining cardiovascular status, vasodilation (e.g., dizziness, lightheadedness, symptomatic hypotension), and bradycardia.1,524

If the patient experiences increases in manifestations of heart failure such as edema during the initiation and titration phases of carvedilol therapy, further increases in carvedilol dosage should be delayed until the patient regains clinical stability; such manifestations may require an increase in diuretic dosage.1,59,524 If increased manifestations of heart failure do not resolve in response to an increase in diuretic dosage, consideration should be given to decreasing the carvedilol dosage or temporarily discontinuing the drug.1 The occurrence of increased manifestations of heart failure during initiation of carvedilol therapy or dosage titration that require dosage decreases or discontinuance of the drug should not prevent future consideration of resuming therapy with or increasing dosage of carvedilol.1,59 If the patient develops manifestations of vasodilation, consideration should be given to decreasing the patient's dosage of diuretic or ACE inhibitor; however, if these dosage reductions do not result in improved circulatory status, carvedilol dosage may be decreased.1 Separating the time of dosing of carvedilol from that of the ACE inhibitor also may reduce vasodilatory symptoms.1,59 If the patient becomes bradycardic (heart rate less than 55 beats/minute), carvedilol dosage should be reduced.1,59 If the patient develops manifestations of worsening heart failure or vasodilation, carvedilol dosage should not be increased until the patient's cardiovascular status is stable.1,59,524

If the patient tolerates the initial dosage, carvedilol dosage may be increased to 6.25 mg twice daily as the immediate-release tablets or to 20 mg once daily as carvedilol phosphate extended-release capsules for 2 weeks.1,59 When increases in dosage are considered, the patient should be observed in a clinical setting for manifestations of hypotension (e.g., dizziness, light-headedness) for 1 hour after administration of the initial dose at the increased dosage.1 Dosage of carvedilol as the immediate-release tablets and carvedilol phosphate as extended-release capsules can be doubled every 2 weeks if necessary (with strict adherence to the monitoring regimen described above) to the highest tolerated dosage that does not exceed the maximum recommended dosage of 50 mg daily (in patients weighing less than 85 kg) and 100 mg daily (in those weighing more than 85 kg) as carvedilol immediate-release tablets and of 80 mg once daily as carvedilol phosphate extended-release capsules.1,59

Left Ventricular Dysfunction After Acute Myocardial Infarction

Prior to initiation of carvedilol therapy for left ventricular dysfunction following acute myocardial infarction (MI), fluid retention should be minimized, and patients should be hemodynamically stable.1,59 Initiation of carvedilol therapy and subsequent dosage adjustments should occur under very close medical supervision, since the risk of cardiac decompensation and/or severe hypotension is highest during the initial 30 days of therapy.1 Therapy may be initiated on an inpatient or outpatient basis after the patient is hemodynamically stable and fluid retention is minimized.1,59

To decrease the likelihood of syncope or excessive hypotension, treatment with carvedilol should be initiated at a low dosage of 6.25 mg twice daily as the immediate-release tablets or 20 mg of carvedilol phosphate once daily as the extended-release capsules.1,59 If the patient tolerates the initial dosage, carvedilol dosage may be increased after 3-10 days to 12.5 mg twice daily as the immediate-release tablets or 40 mg once daily as carvedilol phosphate extended-release capsules, and then to the target dosage of 25 mg twice daily as the immediate-release tablets or 80 mg of carvedilol phosphate once daily as the extended-release capsules.1,59 A lower initial dosage of 3.125 mg twice daily as the immediate-release tablets or 10 mg of carvedilol phosphate once daily as the extended-release capsules and/or a slower rate of dosage titration may be used when clinically indicated (e.g., low blood pressure or heart rate, fluid retention).1,59 Alteration of the recommended dosage regimen is not necessary in patients who received IV or oral treatment with a β-blocker during the acute phase of MI.1,59

Although the optimal duration of β-blocker therapy following MI remains to be clearly established, experts generally recommend that such therapy be continued long-term in post-MI patients with left ventricular systolic dysfunction.525,802,804,1101

Special Populations

Use of carvedilol is not recommended in patients with clinical manifestations of hepatic impairment or with otherwise severe impairment.1,59 (See Contraindications.)

Although the manufacturer makes no specific recommendations for dosage adjustments in patients with renal impairment, plasma concentrations of carvedilol based on comparison of mean plasma concentration-time curves (AUC) reportedly are 40-50% higher in patients with hypertension and moderate to severe renal impairment compared with patients with hypertension and normal renal function receiving carvedilol therapy as the immediate-release tablets.1,59 Although the ranges of AUC values were similar for both groups, mean peak plasma concentrations were approximately 12-26% higher in patients with impaired renal function compared with those in patients with no such impairment.1,59 Carvedilol does not appear to be removed by hemodialysis.1,17,59

If a deterioration in renal function is detected in patients with heart failure, dosage of carvedilol should be decreased or the drug should be discontinued.1

Some clinicians suggest using a reduced initial carvedilol dosage in geriatric patients, since such patients are at increased risk of developing orthostatic hypotension and experience is limited regarding the use of the drug in patients 75 years of age or older.2,18

Contraindications

Bronchial asthma or related bronchospastic conditions.1,59

Second or third degree AV block.1,59

Sick sinus syndrome or severe bradycardia (unless permanent pacemaker is in place).1,59

Cardiogenic shock or decompensated heart failure requiring IV inotropic therapy; initiate carvedilol only after the patient is weaned from IV therapy.1,59

Clinically apparent or otherwise severe hepatic impairment.1,59

History of serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to carvedilol or any ingredient in the formulation.1,59

Warnings/Precautions

Warnings

Abrupt Withdrawal of Therapy

Abrupt withdrawal of carvedilol may exacerbate angina symptoms and/or precipitate myocardial infarction (MI) and ventricular arrhythmias in patients with coronary artery disease or may precipitate thyroid storm in patients with thyrotoxicosis.1,22,59 Therefore, patients receiving carvedilol (especially those with ischemic heart disease) should be warned not to interrupt or discontinue therapy without consulting their clinician.1,22,59 Because coronary artery disease is common and may be undiagnosed, abrupt withdrawal also should be avoided in patients receiving carvedilol for other conditions (e.g., hypertension).1,22,59 When carvedilol is discontinued in patients with coronary artery disease or suspected thyrotoxicosis, the patient should be observed carefully; patients with coronary artery disease should be advised to temporarily limit their physical activity.1,22,59 If exacerbation of angina occurs or acute coronary insufficiency develops after carvedilol therapy is interrupted or discontinued, treatment with the drug should be reinstituted, at least temporarily.1,22,59

If carvedilol therapy, alone or combined with another antihypertensive agent (e.g., a thiazide diuretic), is to be discontinued, dosage should be reduced gradually in a deliberate and progressive manner, if possible.1,20,59 When such cessation of therapy is planned, the manufacturer recommends that therapy with the drug be withdrawn gradually over approximately 1-2 weeks.1,59 Patients should be monitored closely during this period and, if manifestations of withdrawal (e.g., angina, exacerbation of hypertension) develop, dosage should be increased or the drug reinstituted, at least temporarily.1,59

Peripheral Vascular Disease

Possible precipitation or aggravation of arterial insufficiency in patients with peripheral vascular disease.1,59 Use with caution.1,59

Anesthesia and Major Surgery

If carvedilol therapy is continued perioperatively, use particular caution when anesthetic agents that depress myocardial function (e.g., ether, cyclopropane, trichloroethylene) are used.1,59 (See Drug Interactions.)

Diabetes and Hypoglycemia

β-Adrenergic blocking agents (β-blockers) may mask some of the manifestations of hypoglycemia (e.g., tachycardia).1,59 Non-selective β-blockers (e.g., carvedilol) are more likely to potentiate insulin-induced hypoglycemia and delay recovery of serum glucose concentrations.1,59

In patients with heart failure and diabetes mellitus, blood glucose should be monitored when carvedilol therapy is initiated or discontinued or the dosage adjusted, since carvedilol therapy may worsen hyperglycemia.1,59

Thyrotoxicosis

β-Adrenergic blockade may mask clinical signs of hyperthyroidism (e.g., tachycardia).1,59 Abrupt withdrawal of β-blockade may be followed by an exacerbation of symptoms of hyperthyroidism or may precipitate thyroid storm.1,59

General Precautions

Carvedilol shares the toxic potentials of β-adrenergic and α₁-adrenergic blocking agents; observe the usual precautions recommended with these agents.1

Bradycardia

May cause bradycardia; dosage should be reduced if heart rate is less than 55 beats/minute.1,59

Hypotension

May cause hypotension, postural hypotension, or syncope.1,59 Risk is highest in first 30 days of therapy in patients with heart failure.1,59 To decrease risk of orthostatic hypotension, administer with food and strictly adhere to the usual starting dose and titration recommendations.1,22 (See Dosage and Administration.)

Pheochromocytoma

In patients with pheochromocytoma, an α-adrenergic blocking agent should be administered before using a β-blocker.1,59 Although carvedilol has both α- and β-blocking pharmacologic activities, there has been no experience with its use in this condition; use with caution.1,59

Prinzmetal's Variant Angina

Nonselective β-blockers may provoke chest pain in patients with Prinzmetal's variant angina; use with caution.1,59

History of Anaphylactic Reactions

Possible increased reactivity to a variety of allergens; patients may be unresponsive to usual doses of epinephrine used to treat anaphylactic reactions.1,59

Bronchospastic Disease

Bronchospasm reported rarely; deaths secondary to status asthmaticus have been reported following single doses of carvedilol.1 Patients with bronchospastic disease (e.g., chronic bronchitis, emphysema) generally should not receive β-blockers.1,59 Carvedilol should be used in patients with bronchospastic disease only when they are nonresponsive or intolerant of other antihypertensive agents; if used in such patients, the drug should be administered with caution and at the lowest dosage that achieves the desired clinical effect to minimize the drug's inhibition of endogenous or exogenous β-adrenergic agonists.1,59 (See Contraindications under Cautions.) If bronchospasm occurs, dosage should be reduced.1

The manufacturer recommends that carvedilol be used with caution and strict adherence to recommendations regarding dosage titration in patients with heart failure and bronchospastic disease.1,59 If any evidence of bronchospasm occurs during initiation and/or titration of carvedilol, the dosage should be reduced.1,59

Specific Populations

Pregnancy

Category C. 1,59 (See Users Guide.)

Crosses the placenta in rats.1,59 Perinatal and neonatal distress have been reported with other α- and β-blockers.1,59

Lactation

Distributed into milk in rats; not known whether distributed into human milk.1 Because of the risk of adverse effects in the infant, discontinue nursing or the drug, taking into account the importance of the drug to the woman.1

Pediatric Use

Safety and efficacy not established in children younger than 18 years of age.1,59

In a clinical trial in pediatric patients (mean age 6 years, range 2 months to 17 years) with chronic heart failure (NYHA class II-IV), carvedilol resulted in β-blockade activity as demonstrated by a placebo-corrected heart rate reduction of 4-6 beats/minute; however, no clinically important effect on treatment outcome was observed after 8 months of follow-up.1 Common adverse effects included chest pain, dizziness, and dyspnea.1,59

Geriatric Use

No substantial differences in safety or efficacy relative to younger adults, but possibility exists of increased sensitivity to carvedilol in some individuals.1 Some clinicians suggest using a reduced initial carvedilol dosage in geriatric patients, since such patients are at increased risk of developing orthostatic hypotension and experience is limited regarding the use of the drug in patients 75 years of age or older.2,18 Plasma concentrations of carvedilol are about 50% higher in geriatric individuals than in younger individuals.1

Hepatic Impairment

Not recommended for use in patients with manifestations of hepatic impairment or severe hepatic impairment.1,59 (See Contraindications under Cautions.)

Patients with hepatic cirrhosis developed plasma drug concentrations approximately 4-7 times higher than those in healthy individuals after a single dose of immediate-release carvedilol tablets.1,17,59

Renal Impairment

Deterioration of renal function has been reported in patients receiving carvedilol.1,59

Patients at risk appear to be those with low blood pressure (systolic blood pressure less than 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal insufficiency.1,59 Renal function should be monitored in these patients during the dosage titration period; the drug should be discontinued or dosage reduced if worsening of renal function occurs.1,59

Common Adverse Effects

Adverse effects reported in 5% or more of patients with heart failure receiving immediate-release carvedilol tablets include dizziness, headache, fatigue, asthenia, arthralgia, hypotension, bradycardia, generalized edema, diarrhea, nausea, vomiting, hyperglycemia, weight gain, increased BUN, increased nonprotein nitrogen (NPN), increased cough, and abnormal vision.1,59

Adverse effects reported in patients with left ventricular dysfunction following MI receiving immediate-release carvedilol tablets generally were similar to those in patients receiving the drug for the treatment of heart failure.1 Additional adverse effects reported in 3% or more of such patients include anemia, dyspnea, and pulmonary edema.1,59

Adverse effects reported in 2% or more of patients receiving immediate-release carvedilol tablets for the treatment of hypertension include dizziness, bradycardia, diarrhea, insomnia, and postural hypotension.1

Adverse effects reported in 2% or more of patients receiving extended-release carvedilol phosphate capsules for the treatment of hypertension include nasopharyngitis, dizziness, nausea, and peripheral edema.59

Metabolized by cytochrome P-450 (CYP) isoenzymes, principally CYP2D6 and CYP2C9; also metabolized to a lesser extent by CYP3A4, CYP2C19, CYP1A2, CYP2E1.1

Drugs Affecting Hepatic Microsomal Enzymes

Potent inhibitors of CYP2D6 (e.g., fluoxetine, paroxetine, propafenone, quinidine): potential pharmacokinetic interaction (increased plasma concentrations of R (+)-carvedilol); however interactions with carvedilol have not been studied.1

Antidiabetic Agents (Oral and Parenteral [Insulin])

Possible increased hypoglycemic effect.1,59 Blood glucose concentrations should be monitored regularly.1,59

Calcium-channel Blocking Agents

Possible conduction disturbance, rarely with hemodynamic compromise.1,59 Blood pressure and ECG should be monitored during concomitant use with diltiazem or verapamil.1,59

Cardiac Glycosides

Potential pharmacokinetic and pharmacodynamic interaction.1,59 Digoxin concentrations are increased by about 15% in patients receiving concomitant therapy with digoxin and carvedilol.1,59,62 Both cardiac glycosides and carvedilol slow AV conduction and decrease heart rate; concomitant use may increase risk of bradycardia.1,59,62 Digoxin therapy should be carefully monitored when carvedilol dosage is initiated, adjusted, or discontinued.1,59,62

Catecholamine-depleting Agents (e.g., reserpine, MAO inhibitors)

Potential additive effects (e.g., hypotension, bradycardia).1,59 Patients should be monitored closely for symptoms (e.g., vertigo, syncope, postural hypotension).1,59

Cimetidine

Potential decreased carvedilol metabolism and increased (by 30%) bioavailability (area under the plasma concentration-time curve [AUC]) of carvedilol.1 No apparent change in peak plasma concentration of carvedilol.1

Clonidine

Potential additive effects (e.g., hypotension, bradycardia).1,59 If carvedilol is used concomitantly with clonidine, caution should be exercised, particularly when discontinuing therapy; carvedilol generally should be discontinued first, and clonidine continued for several days thereafter with gradual downward dosage titration.1,59

Cyclosporine

Possible increased cyclosporine concentrations.1,59 Cyclosporine concentrations should be closely monitored during carvedilol dosage titration; adjust cyclosporine dosage as necessary.1,59

Fluoxetine

Potential pharmacokinetic and pharmacodynamic interaction; potential for increased plasma concentrations of R (+)-carvedilol that may result in increased α-adrenergic blockade effects (vasodilation).1,59

Glyburide

Pharmacokinetic interaction unlikely.1,59

Hydrochlorothiazide

Pharmacokinetic interaction unlikely.1,59

Myocardial Depressant General Anesthetics (ether, cyclopropane, trichloroethylene)

Potential for increased risk of hypotension and heart failure.1 Use with caution.1

Pantoprazole

No clinically important increases in AUC and peak plasma concentrations of carvedilol reported with concomitant administration of carvedilol and pantoprazole.59

Paroxetine

Potential pharmacokinetic and pharmacodynamic interaction; potential for increased plasma concentrations of R (+)-carvedilol that may result in increased α-adrenergic blockade effects (vasodilation).1,59

Propafenone

Potential pharmacokinetic interaction; potential for increased plasma concentrations of R (+)-carvedilol that may result in increased α-adrenergic blockade effects (vasodilation).1,59

Quinidine

Potential pharmacokinetic interaction: potential for increased plasma concentrations of R (+)-carvedilol that may result in increased α-adrenergic blockade effects (vasodilation).1,59

Rifampin

In a pharmacokinetic study, rifampin decreased peak plasma concentration (by 70%) and AUC (by 70%) of carvedilol.1,59

Torsemide

Pharmacokinetic interaction unlikely.1,59

Warfarin

No effect on steady-state prothrombin times or warfarin pharmacokinetics.1

Description

Carvedilol is a nonselective β-adrenergic blocking agent (β-blocker) with selective α₁-adrenergic blocking activity.1,5,16,17,18,19,59 The principal physiologic action of carvedilol is to competitively block adrenergic stimulation of β-receptors within the myocardium (β₁-receptors) and within bronchial and vascular smooth muscle (β₂-receptors), and to a lesser extent α₁-receptors within vascular smooth muscle.2,17,18,19 The β₁-antagonist activity of carvedilol is similar to that of propranolol and greater than that of labetalol, and the duration of carvedilol's effect is longer than those of labetalol and propranolol.17 Studies in animals indicate that the drug may exert an antioxidant effect on the myocardium and an antiproliferative effect on intimal tissue.2,17,19 The commercially available drug is a racemic mixture of the 2 enantiomers, ( R )[+] and ( S )[-], and both enantiomers have equal α₁-adrenergic blocking activity; however, only the S(-)-enantiomer of carvedilol has β-adrenergic blocking activity.1,2,17 Carvedilol does not exhibit intrinsic sympathomimetic (β₁-agonist) activity1,2 and possesses only weak membrane-stabilizing (local anesthetic) activity.17

Vasodilation resulting in reduced total peripheral resistance mediated through carvedilol's α₁-adrenergic blockade and reduced sympathetic tone appear to play a major role in the drug's hypotensive effect.2,17,19 Carvedilol causes reductions in cardiac output, exercise-induced tachycardia, isoproterenol-induced tachycardia, and reflex orthostatic tachycardia.1,2,17,59 Clinically important β-adrenergic blocking activity of carvedilol usually is evident within 1 hour of oral administration, and the drug's hypotensive effect is similar to that of metoprolol.1,2,17,59 Carvedilol's α₁-adrenergic blocking effects, which contribute to the drug's hypotensive effects, generally are evident within 30 minutes of oral administration and include reductions in phenylephrine-induced pressor effects, vasodilation, and decreased peripheral vascular resistance.1,2,17,59 The dose-dependent hypotensive effect of carvedilol results in blood pressure (systolic and diastolic) reductions of 5-46% with little, if any, reflex tachycardia.2,17 This hypotensive effect occurs approximately 30 minutes after oral administration and has a maximum effect 1.5-7 hours after oral administration.1,2,17

Carvedilol reduces peripheral vascular resistance and blood pressure as a result of its vasodilating effects; the drug produces both arterial and venous dilation.1,59 Carvedilol reduces blood pressure in both supine and standing patients; as a result of α₁-blockade, the effect is most pronounced on standing blood pressure, and orthostatic hypotension can occur.1,59 The manufacturer states that the frequency and severity of orthostatic hypotension may be decreased by administering the drug with food and by strictly adhering to the usual starting dose and titration recommendations.1,59 (See Dosage and Administration.)

The precise mechanism of the beneficial effects of carvedilol in the treatment of heart failure has not been fully elucidated.1,2,17,18,19,59β-Adrenergic blockade and vasodilation generally are associated with reflex tachycardia and peripheral vasoconstriction in therapeutic agents in which one of these pharmacologic effects predominates, but the combined effects of carvedilol appear to attenuate these two major untoward responses by balancing the potential adverse effects associated with adrenergic blockade and vasodilation.17,18,19 The drug's vasodilatory action appears to enable the patient to tolerate the negative inotropic effect of carvedilol during the initiation and titration of therapy in the treatment of compensated heart failure.17,18,19 Chronic adrenergic stimulation and resultant activation of the renin-angiotensin system associated with compensated chronic heart failure result in sodium retention and vasoconstriction that, in turn, can induce further increases in preload and afterload that decrease cardiac output and stimulate additional sympathetic output.17,18,19 Some evidence suggests that the combined adrenergic effects of carvedilol, especially vasodilation, may ameliorate the negative inotropic effects that could otherwise lead to myocardial dysfunction in the compensating heart failure patient.17,18,19

In patients with chronic heart failure and left ventricular dysfunction, carvedilol is associated with improvements in myocardial function through reduction in afterload as evidenced by improved left ventricular ejection fraction, reduced left ventricular volumes, and prevention of progression of left ventricular dilatation.1 Reductions in systemic blood pressure, pulmonary artery pressure, pulmonary capillary wedge pressure, and heart rate were observed in patients with heart failure (New York Heart Association [NYHA] functional class II-IV) receiving angiotensin-converting enzyme (ACE) inhibitors, cardiac glycosides, and/or diuretics after initiating concurrent carvedilol therapy.1 During initial therapy with carvedilol, small and variable responses in cardiac output, stroke volume index, and systemic vascular resistance occur.1 Chronic carvedilol therapy (12 -14 weeks) is associated with reductions in systemic blood pressure, pulmonary artery pressure, right atrial pressure, systemic vascular resistance, and heart rate, and increased stroke volume index.1 Increases (7%) in left ventricular ejection fraction (LVEF) were observed in patients with heart failure (NYHA class II-III) receiving carvedilol at a target dosage of 25-50 mg twice daily for 26-52 weeks.1 The effect of carvedilol on LVEF was dose-related, with increases of 5, 6, and 8% reported with twice-daily doses of 6.25 mg, 12.5 mg, and 25 mg, respectively.1

The precise mechanism of the beneficial effects of carvedilol in the treatment of left ventricular dysfunction following myocardial infarction (MI) has not been fully elucidated.1,59

Carvedilol is rapidly and extensively absorbed following oral administration.1 Food decreases the rate of the drug's absorption (i.e., increases time to peak plasma concentration), but not the extent (i.e., no effect on bioavailability) of absorption.1 Administration with food may decrease the risk of orthostatic hypotension.1 Carvedilol is substantially distributed into extravascular tissues.1 The half-life of carvedilol is 7-10 hours;1 5-9 hours for R (+)-carvedilol, and 7-11 hours for S (-)-carvedilol.1 The drug is more than 98% bound to plasma proteins.1 Carvedilol is extensively metabolized; phenol ring demethylation and hydroxylation produce 3 metabolites with β-adrenergic blocking activity and (weak) vasodilating activity.1 Plasma concentrations of active metabolites are about 10% those of carvedilol.1 The 4'-hydroxyphenyl metabolite is 13 times more potent than carvedilol in β-adrenergic blocking activity.1 Carvedilol is excreted principally in feces as metabolites; less than 2% is excreted in urine unchanged.1

Advice to Patients

Importance of taking carvedilol exactly as prescribed.1 Importance of taking with food.1

Importance of advising patients receiving carvedilol phosphate extended-release capsules not to crush or chew the capsules.59

Importance of not interrupting or discontinuing therapy without consulting clinician.1,59 When discontinuing therapy, importance of advising patients to temporarily limit physical activity.1,59

Importance of advising patients to sit or lie down and avoid hazardous tasks (e.g., driving) if dizziness or fatigue occur.1,59 Importance of informing clinician if dizziness or faintness from decreased blood pressure occurs; dosage adjustment may be necessary.1,59

Importance of diabetic patients informing clinician if changes in blood glucose concentrations occur.1 Importance of warning patients receiving insulin or oral hypoglycemic agents or those subject to spontaneous hypoglycemia about these potential effects.1

Importance of immediately informing clinician at the first sign or symptom (e.g., weight gain, shortness of breath) of heart failure.1,59

Importance of informing contact lens wearers that they may experience decreased lacrimation.1

Importance of advising patients undergoing major surgery to inform anesthesiologist or dentist that they are receiving the drug.1

Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs.1

Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1

Importance of informing patient of other important precautionary information.1 (See Cautions.)

Additional Information

Overview^® (see Users Guide). For additional information on this drug until a more detailed monograph is developed and published, the manufacturer's labeling should be consulted. It is essential that the manufacturer's labeling be consulted for more detailed information on usual cautions, precautions, contraindications, potential drug interactions, laboratory test interferences, and acute toxicity.

1. GlaxoSmithKline. Coreg^® (carvedilol) tablets prescribing information. Research Triangle Park, NC; 2008 Jul.

2. Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs . 1997; 54:161-85. [PubMed 9211087]

4. Anon. Drugs for hypertension. Med Lett Drugs Ther . 1993; 35:55-60. [PubMed 8099706]

5. Anon. Carvedilol for heart failure. Med Lett Drugs Ther . 1997; 39:89-91. [PubMed 9323960]

6. Colucci WS, Packer M, Bristow MR et al et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation . 1996; 94:2800-6. [PubMed 8941105]

7. Bristow MR, Gilbert EM, Abraham WT et al et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation . 1996; 94:2807-16. [PubMed 8941106]

8. Packer M, Colucci WS, Sackner-Bernstein JD et al et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation . 1996; 94:2793-9. [PubMed 8941104]

9. Cohn JN, Fowler MB, Bristow MA et al et al. Effect of carvedilol in severe chronic heart failure. J Am Coll Cardiol . 1996; 27(Suppl A):169A.

10. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet . 1997; 349:375-80. [PubMed 9033462]

11. Packer M, Bristow MR, Cohn JN et al. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med . 1996; 334:1349-55. [PubMed 8614419]

12. Pfeffer MA, Stevenson LW. β-adrenergic blocking agents and survival in heart failure. N Engl J Med . 1996; 334:1396-7. [PubMed 8614427]

13. Moyé LA, Abernethy D. Carvedilol in patients with chronic heart failure. N Engl J Med . 1996; 335:1318. [PubMed 8992327]

14. von Olshausen K, Pop T, Berger J. Carvedilol in patients with chronic heart failure. N Engl J Med . 1996; 335:1318-9. [PubMed 8992328]

15. Packer M, Cohn JN, Colucci WS. Carvedilol in patients with chronic heart failure. N Engl J Med . 1996; 335:1319-20.

16. SmithKline Beecham Pharmaceuticals. Coreg^® (carvedilol) pharmacy use and counseling guide. Philadelphia, PA; 1997 Jun.

17. McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs . 1993; 45:232-58. [PubMed 7681374]

18. Cleland JGF, Swedberg K. Carvedilol for heart failure, with care. Lancet . 1996; 347:1199-201. [PubMed 8622445]

19. Krum H. β-adrenoceptor blocking agents in chronic heart failure—a review. Br J Clin Pharmacol . 1997; 44:111-8. [PubMed 9278193][PubMedCentral]

20. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). Bethesda, MD: National Institutes of Health; 1997 Nov. (NIH publication No. 98-4080.)

22. Pharmacia & Upjohn, Kalamazoo, MI: Personal communication.

23. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: apporaches to the prevention of heart failure. Am J Cardiol . 1999; 83:9A-38A

24. Metra M, Nardi M, Raffaele G et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol . 1994; 24:1678-87. [PubMed 7963115]

25. Olsen SL, Gilbert EM, renlund DG et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol . 1995; 25:1225-31. [PubMed 7722114]

26. Krum H, Sackner-Bernstein JD, Goldsmith RL et al. Double-blind placebo controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation . 1995; 92:1499-506. [PubMed 7664433]

27. Bristow MR, Gilbert EM, Abraham WT et al. Effect of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy. Circulation . 1996; 94(Suppl I):I664.

28. Lechat P, Packer M, Chalon S et al. Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation . 1998; 98:1184-91. [PubMed 9743509]

31. Packer M, Coats AJS, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med . 2001; 344:1651-8. [PubMed 11386263]

32. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol . 2001. From ACC website. [Web]

33. Califf RM, O'Connor CM. β-Blocker therapy for heart failure. The evidence is in, now the work begins. JAMA . 2000; 283:1335-6. [PubMed 10714735]

34. Hjalmarson A, Goldstein S, Fagerberg B et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA . 2000; 283:1295-1302. [PubMed 10714728]

35. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA . 2002; 288:3039-35. [PubMed 12479770]

36. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-riskhypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA . 2002; 288:2981-97. [PubMed 12479763]

38. Douglas JG, Bakris GL, Epstein M et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163:525-41.

40. The Guidelines Subcommitee of the WHO/ISH Mild Hypertension Liaison Committee. 1999 guidelines for the management of hypertension. J Hypertension . 1999; 17:392-403.

42. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension . 2000; 35:1021-4. [PubMed 10818056]

43. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension . 2000; 35:1019-20. [PubMed 10818055]

44. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis . 2000; 36:646-61. [PubMed 10977801]

45. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA . 2005; 293:1595-607. [PubMed 15811979]

46. Neaton JD, Kuller LH. Diuretics are color blind. JAMA . 2005; 293:1663-6. [PubMed 15811986]

47. Thadani U. Beta blocking agents in hypertension. Am J Cardiol . 1983; 52:10-5D.

48. Conolly ME, Kersting F, Dollery CT. The clinical pharmacology of beta-adrenoceptor-blocking drugs. Prog Cardiovasc Dis . 1976; 19:203-34. [PubMed 10600]

49. Shand DG. State-of-the-art: comparative pharmacology of the β-adrenoceptor blocking drugs. Drugs . 1983; 25(Suppl 2):92-9.

50. Breckenridge A. Which beta blocker? Br Med J . 1983; 286:1085-8.

51. Anon. Choice of a beta-blocker. Med Lett Drugs Ther . 1986; 28:20-2. [PubMed 2869400]

52. Wallin JD, Shah SV. β-Adrenergic blocking agents in the treatment of hypertension: choices based on pharmacological properties and patient characteristics. Arch Intern Med . 1987; 147:654-9. [PubMed 2881524]

53. McDevitt DG. β-Adrenoceptor blocking drugs and partial agonist activity: is it clinically relevant? Drugs . 1983; 25:331-8.

54. McDevitt DG. Clinical significance of cardioselectivity: state-of-the-art. Drugs . 1983; 25(Suppl 2):219-26.

55. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med . 1981; 305:500-6. [PubMed 6114433]

56. Thadani U, Davidson C, Chir B et al. Comparison of the immediate effects of five β-adrenoceptor-blocking drugs with different ancillary properties in angina pectoris. N Engl J Med . 1979; 300:750-5. [PubMed 581782]

57. Lewis RV, McDevitt DG. Adverse reactions and interactions with β-adrenoceptor blocking drugs. Med Toxicol . 1986; 1:343-61. [PubMed 2878346]

58. Frishman WH. Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution. Am Heart J . 1987; 113:1190-8. [PubMed 2883867]

59. GlaxoSmithKline. Coreg CR^® (carvedilol phosphate) extended-release capsules prescribing information. Research Triangle Park, NC; 2008 Apr.

60. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation . 2005; 112:e154-235. [PubMed 16160202]

61. Colucci WS. Landmark study: the carvedilol post-infarct survival control in left ventricular dysfunction study (CAPRICORN). Am J Cardiol . 2004; 93(suppl):13B-16B. [PubMed 15144931]

62. GlaxoSmithKline, Philadelphia, PA: Personal communication.

63. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet . 2002;359:995-1003. [PubMed 11937178]

500. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Bethesda, MD: National Institutes of Health; 2004 Aug. (NIH publication No. 04-5230.)

501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA . 2014; 311:507-20. [PubMed 24352797]

502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens . 2013; 31:1281-357. [PubMed 23817082]

503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension . 2014; 63:878-85. [PubMed 24243703]

504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) . 2014; 16:14-26. [PubMed 24341872]

505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med . 2014; 160:499-503. [PubMed 24424788]

506. Mitka M. Groups spar over new hypertension guidelines. JAMA . 2014; 311:663-4. [PubMed 24549531]

507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. JAMA . 2014; 311:474-6. [PubMed 24352710]

508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA . 2014; 311:477-8. [PubMed 24352759]

515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med . 2014; 81:178-88. [PubMed 24591473]

523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation . 2012; 126:e354-471.

524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation . 2013; 128:e240-327.

525. Smith SC, Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation . 2011; 124:2458-73. [PubMed 22052934]

526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke . 2014; :. [PubMed 24788967]

527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation . 2013; 127:e362-425. [PubMedCentral]

530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. J Clin Hypertens (Greenwich) . 2014; 16:246-8. [PubMed 24641124]

536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl . 2012: 2: 337-414.

701. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J . 2016; :. [PubMedCentral]

702. McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014; 371:993-1004. [PubMed 25176015]

703. Ansara AJ, Kolanczyk DM, Koehler JM. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. J Clin Pharm Ther . 2016; 41:119-27. [PubMed 26992459]

707. Amgen Inc. Corlanor^® (ivabradine) tablets prescribing information. Thousand Oaks, CA; 2015 Apr.

708. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet . 2010; 376:875-85. [PubMed 20801500]

709. Urbanek I, Kaczmarek K, Cygankiewicz I et al. Risk-benefit assessment of ivabradine in the treatment of chronic heart failure. Drug Healthc Patient Saf . 2014; 6:47-54. [PubMed 24855390][PubMedCentral]

710. Di Franco A, Sarullo FM, Salerno Y et al. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. Am J Cardiovasc Drugs . 2014; 14:101-10. [PubMed 24327100]

711. Schuster A, Tang WH. Ivabradine in heart failure: to SHIFT or not to SHIFT. Curr Heart Fail Rep . 2011; 8:1-3. [PubMed 21057902]

712. Borer JS, Böhm M, Ford I et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J . 2012; 33:2813-20. [PubMed 22927555][PubMedCentral]

800. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation . 2016; :.

802. Bockstall K, Bangalore S. How long should we continue beta-blockers after MI? 2017 Jan 23. From ACC website. Accessed 2017 May 17. [Web]

804. Kezerashvili A, Marzo K, De Leon J. Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it “ok” to discontinue?. Curr Cardiol Rev . 2012; 8:77-84. [PubMed 22845818][PubMedCentral]

806. Freemantle N, Cleland J, Young P et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ . 1999; 318:1730-7. [PubMed 10381708][PubMedCentral]

1101. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation . 2012; 126:e354-471.

1200. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension . 2018; 71:el13-e115. [PubMed 29133356]

1201. Bakris G, Sorrentino M. Redefining hypertension - assessing the new blood-pressure guidelines. N Engl J Med . 2018; 378:497-499. [PubMed 29341841]

1202. Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med . 2018; 168:351-358. [PubMed 29357392]

1207. Burnier M, Oparil S, Narkiewicz K et al. New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. Blood Press . 2018; 27:62-65. [PubMed 29447001]

1209. Qaseem A, Wilt TJ, Rich R et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med . 2017; 166:430-437. [PubMed 28135725]

1210. SPRINT Research Group, Wright JT, Williamson JD et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med . 2015; 373:2103-16. [PubMed 26551272]

1216. Taler SJ. Initial treatment of hypertension. N Engl J Med . 2018; 378:636-644. [PubMed 29443671]

1220. Cifu AS, Davis AM. Prevention, detection, evaluation, and management of high blood pressure in adults. JAMA . 2017; 318:2132-2134. [PubMed 29159416]

1222. Bell KJL, Doust J, Glasziou P. Incremental benefits and harms of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline. JAMA Intern Med . 2018; 178:755-7. [PubMed 29710197]

1223. LeFevre M. ACC/AHA hypertension guideline: what is new? what do we do?. Am Fam Physician . 2018; 97(6):372-3. [PubMed 29671534]

1224. Brett AS. New hypertension guideline is released. From NEJM Journal Watch website. Accessed 2018 Jun 18. [Web]

1229. Ioannidis JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. JAMA . 2018; 319(2):115-6. [PubMed 29242891]

1235. Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens . 2017; 11(1):54-65. [PubMed 28057444]